A Phase 2 interventional study of Surovatamig in Primary Membranous Nephropathy, sponsored by AstraZeneca. Recruiting at 27 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Glomerulonephritis, Membranous with a site in United States — 13 open to participants now, 16 under way, 5 of them phase 3. Glomerulonephritis, Membranous · United States.
Among the 35 studies in Glomerulonephritis, Membranous with a site in United States, this one is the 13th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 7 of the 15 other live ones, and was the 33rd registered.
146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.
Browse Glomerulonephritis, Membranous studies →13 of the 35 studies in Glomerulonephritis, Membranous with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Amgen · Sites in United States
Ages 18–79
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Vertex Pharmaceuticals Incorporated · Sites in United States, Australia, Brazil and 11 more countries
Ages 18–75
Alexion Pharmaceuticals, Inc. · Sites in United States, Argentina, Australia and 7 more countries
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 7 · Phase 4 4
First in 2002; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 43 is close to the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.
Median enrollment 31 across the 32 interventional studies, 1,000 across the 3 observational. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 35 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 2 studies filed under Glomerulonephritis, Membranous — fewer than ten, so there is no comparison to draw.
3 of the studies in Glomerulonephritis, Membranous with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05707377Phase 3BeOne MedicinesA Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy | 2027-10 |
| NCT07157787Alexion Pharmaceuticals, Inc.Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | 2027-07-02 |
| NCT07096843Climb Bio, Inc.A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Glomerulonephritis, Membranous with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
This is a Phase II open-label study to assess the safety, tolerability, Pharmacokinetics, and efficacy of surovatamig in adult participants with pMN, who are positive for anti-PLA2R antibodies and have heavy and persistent proteinuria with a high risk of progressing to end stage kidney disease.
The study will be conducted across approximately 30 to 40 study sites in approximately 10 countries. The study consists of 2 parts (Part A Multiple ascending with sentinel dosing and Part B Multiple ascending doses), with each consisting of 3 periods (ie, screening period, treatment period, and follow-up period; up to 26 months in total).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
8. History of chronic significant respiratory disease. 9. Significant opportunistic infection in the medical history deemed relevant by the Investigator.
10. Abnormal vital sign after 10 minutes sitting at rest. 11. Administration of such as prednisolone at doses exceeding 20 mg or an equivalent agent \< 2 months before screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Surovatamig
Drug: Surovatamig
Participants will receive Surovatamig subcutaneously
Number of participants with adverse events.
To assess the safety and tolerability of surovatamig on adverse events, including Adverse events, Serious adverse events, Adverse event of special interests, and Adverse events leading to discontinuation of surovatamig.
Time frame: Through study completion, an average of 2 years
Change from baseline in UPCR (from 24-hour urine collection or the intended 24-hour urine collection)
To assess the effect of surovatamig on proteinuria
Time frame: At 6 months
Percentage of participants achieving complete or partial remission of pMN
To evaluate the proportion of participants who achieve partial and/or complete remission
Time frame: At 24 months
Percentage of participants achieving complete remission of pMN
To evaluate the proportion of participants who achieved complete remission
Time frame: At 24 months
Percentage of participants achieving partial remission of pMN
To evaluate the proportion of participants who achieve partial remission
Time frame: At 24 months
Change from baseline in UPCR (from 24-hour urine collection or the intended 24-hour urine collection)
To assess the effect of surovatamig on proteinuria
Time frame: At 24 months
Change from baseline in anti-PLA2R antibody titer
To evaluate anti-PLA2R antibodies in blood
Time frame: At 24 months
Change from baseline in B-cell count in peripheral blood
To assess the effect of surovatamig by assessment of B-cell depletion in blood
Time frame: At 24 months
Time to relapse after complete or partial remission
Time to relapse after complete or partial remission
Time frame: At 24 months
Time to a ≥ 3 months sustained reduction of eGFR
Time to a sustained reduction of eGFR
Time frame: From Baseline to 24 months
Change from baseline in patient-reported experience of symptoms associated with pMN
To evaluate the change in patient-reported experience
Time frame: Through study completion, an average of 2 years
Serum PK parameters of surovatamig, AUC Area under the plasma concentration versus time curve
To characterise the PK of surovatamig
Time frame: Through study completion, an average of 2 years
Treatment-emergent ADAs
To evaluate the immunogenicity of surovatamig
Time frame: Through study completion, an average of 2 years
Serum PK parameters of surovatamig, as Cmax (Peak Plasma Concentration)
To characterise the PK of surovatamig
Time frame: Through study completion, an average of 2 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Oct 2028, 30 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Apr 2028 → Oct 2028 and completion Oct 2029 → Apr 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Surovatamig
Glomerulonephritis, Membranous →